Targeting the cytokine storm with tocilizumab (a humanized anti-IL-6 monoclonal antibody) or dexamethasone has shown promising effects in reducing COVID-19 severity and mortality in severely ill patients (Sanders et al., 2020; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020; Xu X. et al., 2020). Here, IL6 is linked to COVID-19.